GLP-1, GIP, and Glucagon: The Evolution of Metabolic Agonists

The scientific arc

Over two decades, incretin pharmacology has evolved from single-receptor GLP-1 agonism through dual-receptor GLP-1/GIP agonism to triple-receptor GLP-1/GIP/GCGR engagement. Each generation has expanded the pharmacological toolkit available to researchers studying metabolic disease, and each has produced increasingly pronounced effects on glucose homeostasis and body composition in both preclinical models and clinical trials.

This article traces that progression and explains why each step adds something distinct.

Generation 1: selective GLP-1 receptor agonism

The foundational class. GLP-1 (glucagon-like peptide-1) is an incretin hormone secreted by enteroendocrine L-cells after nutrient ingestion. Its receptor is a class B GPCR coupled to Gαs/cAMP signaling.

Key compounds for research:

• Exenatide / Exendin-4 — Heloderma suspectum-derived, 39 aa, useful as a DPP-4-resistant pharmacological probe
• Liraglutide — C-16 acylated, ~13-hour half-life
• Semaglutide — C-18 diacid acylation, ~165-hour half-life, the dominant research reference

Physiological effects:

• Glucose-dependent insulin secretion potentiation
• Glucagon suppression (glucose-dependent)
• Delayed gastric emptying
• Central satiety through hypothalamic and hindbrain GLP-1R
• Cardiovascular and renal protective signals (outcome-trial evidence)

Generation 2: dual GLP-1/GIP receptor agonism

Glucose-dependent insulinotropic polypeptide (GIP) is the other major incretin, secreted by intestinal K-cells. Early work suggested GIP pharmacology was of limited therapeutic interest because GIP response is blunted in type 2 diabetes. Dual agonism changed that picture.

Key compound: Tirzepatide (LY3298176) — 39-aa peptide with GIP backbone, engineered to engage both GIPR and GLP-1R

Why adding GIP matters:

• GIPR activation may restore β-cell responsiveness when paired with sustained GLP-1R signaling
• GIP engages adipose tissue biology directly — lipid storage, lipolysis, adipocyte insulin sensitivity
• Dual agonism may produce distinct downstream signaling (biased pharmacology)
• CNS GIPR in hypothalamic and hindbrain nuclei may amplify satiety pathways

Clinical outcome trials showed greater weight reduction and glycemic improvement than selective GLP-1R agonists — validating the dual-agonist hypothesis.

Generation 3: triple GLP-1/GIP/GCGR agonism

The glucagon receptor (GCGR) is the third arm. Glucagon is traditionally associated with hepatic glucose output and is thought "bad" in diabetes — but at the right pharmacological balance, glucagon receptor activation also drives energy expenditure and hepatic lipid catabolism.

Key compound: Retatrutide (LY3437943) — triple GLP-1R/GIPR/GCGR agonist

The three mechanisms combined:

1. GLP-1 — appetite suppression, delayed gastric emptying, glucose-dependent insulin secretion
2. GIP — insulin sensitivity, adipose biology, potentially enhanced satiety
3. GCGR — energy expenditure, hepatic lipid oxidation, thermogenic tone

Published trial data show the most pronounced weight reduction and hepatic steatosis improvement yet observed — at the cost of more pronounced GI adverse events during titration.

Beyond triple: what's next

Research is now exploring:

• Amylin/GLP-1 co-agonists — CagriSema combining cagrilintide + semaglutide
• GLP-1/Glucagon dual agonists (skipping GIP)
• Oral incretin peptides — non-peptide small-molecule GLP-1R agonists
• Biased agonists — selectively targeting specific downstream pathways while avoiding tolerability limitations

Research implications

Each generation brings distinct opportunities and complications:

• Single agonists remain the cleanest pharmacological tool for isolated GLP-1R studies
• Dual agonists are essential for studies of combined incretin biology or advanced obesity models
• Triple agonists are the leading research tool for maximum-effect metabolic models but require careful control of confounding GCGR-mediated hepatic effects

Related reading

• /blog/semaglutide-glp-1-receptor-agonist-research-pharmacology — GLP-1R pharmacology deep dive
• /blog/tirzepatide-dual-incretin-glp-1-gip-research — dual agonism
• /blog/retatrutide-obesity-models-triple-agonist — triple agonist mechanism
• /blog/glp-1-agonists-retatrutide-research-overview-benefits-models — broad class overview
• /compare/semaglutide-vs-tirzepatide — mono vs dual
• /compare/tirzepatide-vs-retatrutide — dual vs triple
• /compare/semaglutide-vs-retatrutide — mono vs triple
• /category/weight-loss-research — catalog

RUO disclaimer

For laboratory research use only. Not intended to diagnose, treat, cure, or prevent any disease. Not for human consumption outside approved research settings.